{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihyrkeh7p2glapyiyjv67eoitphokryw3u4hmdxm7gudf7zjg6nqm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mp4nejcjlxf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreif4jers6upgig22r5ahadm7cjc5k6diafp64jzwtnb3vk2vdvqzlm"
    },
    "mimeType": "image/jpeg",
    "size": 443749
  },
  "path": "/news/2026-06-radioligand-therapy-her2-positive-cancers.html",
  "publishedAt": "2026-06-25T10:00:11.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.",
  "title": "Radioligand therapy for HER2-positive cancers enters human trials for the first time"
}